Xeris Biopharma Holdings, Inc. 4

Kevin McCulloch, President and COO of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock under a Rule 10b5-1 plan at an average price of about $8.49 per share.

On September 1, 2026, Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., sold 15,000 shares of the company’s common stock at a weighted average price of approximately $8.4872 per share, for total proceeds of about $127,308, under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. Following this sale, he reported direct ownership of 1,639,208 shares of common stock and indirect beneficial ownership of an additional 25,000 shares held by his spouse, for which he disclaimed beneficial ownership except to the extent of his pecuniary interest.

Filing Facts

CIK

1867096

Ticker

XERS

Form

4

Source Type

fda

Accession

0002031695-26-000011

Alert Tier

6